SXTC — China SXT Pharmaceuticals Share Price
Last trade - 00:00- $1.65m
- -$14.65m
- $1.93m
- 29
- 99
- 12
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.11 | ||
| Price to Tang. Book | 0.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.91 | ||
| EV to EBITDA | -2.3 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 40.41% | ||
| Return on Equity | 57.63% | ||
| Operating Margin | 340.71% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.16 | 4.78 | 2.6 | 1.97 | 1.93 | n/a | n/a | -22.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The Company sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- July 4th, 2017
- Public Since
- January 4th, 2019
- No. of Employees
- 75
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 723,046
- Address
- 178 Taidong Road North, TAIZHOU, 225300
- Web
- https://www.sxtchina.com/
- Phone
- +86 52386298290
- Auditors
- ZH CPA LLP
Upcoming Events for SXTC
Similar to SXTC
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in China SXT Pharmaceuticals are trading at $2.28. This share price information is delayed by 15 minutes.
Shares in China SXT Pharmaceuticals last closed at $2.28 and the price had moved by -71.92% over the past 365 days. In terms of relative price strength the China SXT Pharmaceuticals share price has underperformed the S&P500 Index by -74.68% over the past year.
There is no consensus recommendation for this security.
Find out moreChina SXT Pharmaceuticals does not currently pay a dividend.
China SXT Pharmaceuticals does not currently pay a dividend.
China SXT Pharmaceuticals does not currently pay a dividend.
To buy shares in China SXT Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.28, shares in China SXT Pharmaceuticals had a market capitalisation of $1.65m.
Here are the trading details for China SXT Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SXTC
Based on an overall assessment of its quality, value and momentum China SXT Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like China SXT Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -45.98%.
As of the last closing price of $2.28, shares in China SXT Pharmaceuticals were trading -47.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The China SXT Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on China SXT Pharmaceuticals' directors